Fulgent Genetics, Inc.
About Fulgent Genetics, Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $322.7M
- Net income
- -$60.5M
- Total assets
- $1.2B
- Market cap
- $543.9M
- Gross margin
- 40.6%
- Operating margin
- -28.2%
- Net margin
- -19.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $322.7M
- Cost of revenue
- $191.8M
- Gross profit
- $130.9M
- Operating expenses
- $222.0M
- Operating income
- -$91.1M
- Income tax
- -$8.4M
- Net income
- -$61.6M
Balance sheet
- Total assets
- $1.2B
- Current assets
- $550.5M
- Total liabilities
- $106.8M
- Current liabilities
- $85.0M
- Shareholders’ equity
- $1.1B
Cash flow
- Operating cash flow
- -$101.6M
- Investing cash flow
- $111.4M
- Financing cash flow
- -$14.8M
- Net cash flow
- -$5.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $543.9M
- Shares outstanding
- 28.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 29, 2016
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $60.5M in FY2025.
- Revenue declined 67% from FY2021 to FY2025.
- Gross margin of 40.6%, net margin -19.1%.
- Trading 39% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Fulgent Genetics, Inc..
Write a review
News about Fulgent Genetics, Inc.
News & sentiment via Polygon.io
